TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07486713: Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Sponsor: Rigel Pharmaceuticals · Phase: PHASE4 · Area: ONCOLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$591,360

Rescue Site Savings

+$406,560

Unlock Full NCT07486713 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07486713 Rescue Dossier →